Trade Equillium, Inc. - EQ CFD

Add to favourite

0.4795

3.96%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.0226

Long position overnight fee

-0.023679%

Short position overnight fee

0.001457%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	0.5178
Open	0.4341
1-Year Change	-79.41%
Day's Range	0.4341 - 0.4978

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 1, 2025	0.5178	0.1100	26.97%	0.4078	0.5457	0.4078
Mar 31, 2025	0.3901	-0.0077	-1.94%	0.3978	0.4070	0.3578
Mar 28, 2025	0.4032	-0.0346	-7.90%	0.4378	0.4378	0.3782
Mar 27, 2025	0.4079	-0.0911	-18.26%	0.4990	0.5713	0.4079
Mar 26, 2025	0.7404	-0.0474	-6.02%	0.7878	0.7878	0.7049
Mar 25, 2025	0.7628	-0.0350	-4.39%	0.7978	0.8079	0.7628
Mar 24, 2025	0.8058	0.0278	3.57%	0.7780	0.8175	0.7688
Mar 21, 2025	0.7580	-0.0200	-2.57%	0.7780	0.7879	0.7400
Mar 20, 2025	0.7878	-0.0100	-1.25%	0.7978	0.7979	0.7690
Mar 19, 2025	0.7978	0.0062	0.78%	0.7916	0.8318	0.7700
Mar 18, 2025	0.7789	0.0136	1.78%	0.7653	0.7789	0.7644
Mar 17, 2025	0.7678	0.0450	6.23%	0.7228	0.7701	0.7228
Mar 14, 2025	0.7478	0.0000	0.00%	0.7478	0.7728	0.7478
Mar 13, 2025	0.7596	0.0106	1.42%	0.7490	0.7696	0.7356
Mar 12, 2025	0.7356	0.0358	5.12%	0.6998	0.7587	0.6998
Mar 11, 2025	0.7074	0.0039	0.55%	0.7035	0.7293	0.6728
Mar 10, 2025	0.7401	-0.0479	-6.08%	0.7880	0.7880	0.7125
Mar 7, 2025	0.7619	0.0141	1.89%	0.7478	0.8160	0.7478
Mar 6, 2025	0.7676	0.0798	11.60%	0.6878	0.7869	0.6878
Mar 5, 2025	0.7178	0.0100	1.41%	0.7078	0.7245	0.6878

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Equillium, Inc. Company profile

About Equillium Inc

Equillium, Inc. is a clinical-stage biotechnology company. The Company develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The Company's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The Company's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. It also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Equillium Inc revenues was not reported. Net loss increased 31% to $39.1M. Higher net loss reflects Research and development - Balancing val increase of 30% to $24.4M (expense), General and administrative - Balancing increase of 11% to $9M (expense), Other expense, net decrease from $358K (income) to $250K (expense).

Industry:

Pharmaceuticals (NEC)

2223 Avenida de La Playa Ste 105
LA JOLLA
CALIFORNIA 92037-3217
US